{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:55:30Z","timestamp":1792418130469,"version":"4.4.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Systemic glucocorticoids remain an important but problematic treatment option in high-risk IgA nephropathy, offering kidney protection at the cost of clinically relevant toxicity. Recent serum proteomic analyses embedded within the randomized TESTING trial provide a new framework for identifying patients most likely to benefit from methylprednisolone. In 241 Chinese participants with IgA nephropathy, longitudinal profiling of 479 serum samples showed that methylprednisolone significantly modulated 302 proteins involved in cytoskeletal regulation, extracellular matrix interactions, immunometabolism, coagulation, protein turnover, and related pathways. Importantly, complement- and endothelial injury-associated pathways were incompletely modified and remained linked to adverse kidney outcomes, suggesting residual disease mechanisms that may require complementary targeted therapies. Among baseline proteins, leptin and C1QTNF5 emerged as practical candidate biomarkers of glucocorticoid responsiveness, improving prediction of treatment efficacy beyond conventional clinical variables.\u00a0These findings support a shift from purely prognostic risk stratification toward treatment-informed precision medicine in IgA nephropathy. However, the biomarker model requires prospective validation across diverse populations, steroid regimens, and background therapies, and future tools must integrate both predicted kidney benefit and treatment-related harm. If confirmed, serum proteomics could help clinicians move beyond population-average steroid decisions toward biologically guided selection of patients most likely to benefit while avoiding unnecessary toxicity.<\/jats:p>","DOI":"10.1093\/ckj\/sfag345","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:56:22Z","timestamp":1790769382000},"source":"Crossref","is-referenced-by-count":0,"title":["Corticosteroids, serum proteins, and the next phase of precision medicine in IgA nephropathy"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6616-1996","authenticated-orcid":false,"given":"Carmine","family":"Zoccali","sequence":"first","affiliation":[{"name":"Istituto di Biologia e Genetica Molecolare (BIOGEM) , Ariano Irpino ,","place":["Italy"]},{"name":"Associazione Ipertensione Nefrologia e Trapianto Renale (IPNET) , Reggio Calabria ,","place":["Italy"]},{"name":"Division of Nephrology, University Hospital, Rheinisch-Westf\u00e4lische Technische Hochschule (RWTH) Aachen , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[{"name":"Istituto di Biologia e Genetica Molecolare (BIOGEM) , Ariano Irpino ,","place":["Italy"]},{"name":"Division of Nephrology, University Hospital, Rheinisch-Westf\u00e4lische Technische Hochschule (RWTH) Aachen , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026101909245908000_bib1","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"J Am Med Assoc"},{"key":"2026101909245908000_bib2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000001208","article-title":"Glucocorticoid-modulated molecular signatures and prediction of treatment efficacy in IgA nephropathy","author":"Wang","year":"2026","journal-title":"J Am Soc Nephrol"},{"key":"2026101909245908000_bib3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.kint.2026.01.007","article-title":"Predicting steroid treatment benefit in IgA nephropathy: are we ready for precision care?","volume":"109","author":"Rizk","year":"2026","journal-title":"Kidney Int"},{"key":"2026101909245908000_bib4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1681\/ASN.0000000796","article-title":"Predictive value of the Oxford Classification for the effect of glucocorticoid therapy in IgA nephropathy","volume":"37","author":"Shi","year":"2026","journal-title":"J Am Soc Nephrol"},{"key":"2026101909245908000_bib5","doi-asserted-by":"publisher","first-page":"9833","DOI":"10.1038\/s41598-017-10490-z","article-title":"Loss of the podocyte glucocorticoid receptor exacerbates proteinuria after injury","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"2026101909245908000_bib6","doi-asserted-by":"publisher","first-page":"101323","DOI":"10.11131\/2018\/101323","article-title":"The role of glucocorticoid receptors in podocytes and nephrotic syndrome","volume":"5","author":"Zhao","year":"2018","journal-title":"Nucl Recept Res"},{"key":"2026101909245908000_bib7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial","volume":"105","author":"Wimbury","year":"2024","journal-title":"Kidney Int"},{"key":"2026101909245908000_bib8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.kint.2025.01.014","article-title":"Treatment of patients with IgA nephropathy: a call for a new paradigm","volume":"107","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"2026101909245908000_bib9","doi-asserted-by":"publisher","first-page":"106396","DOI":"10.1016\/j.ebiom.2026.106396","article-title":"Individualized treatment effects of corticosteroids in IgA nephropathy","volume":"130","author":"Hoelscher","year":"2026","journal-title":"EBioMedicine"},{"key":"2026101909245908000_bib10","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1080\/08830185.2026.2672518","article-title":"Leptin in metabolic-immune crosstalk: mechanisms of T cell regulation and implications for autoimmune disease therapy","volume":"45","author":"Xiao","year":"2026","journal-title":"Int Rev Immunol"},{"key":"2026101909245908000_bib11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1055\/s-0032-1333299","article-title":"Regulation and function of C1Q\/TNF-related protein-5 (CTRP-5) in the context of adipocyte biology","volume":"121","author":"Schmid","year":"2013","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2026101909245908000_bib12","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/ckj\/sfad199","article-title":"Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis","volume":"16","author":"Lee","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026101909245908000_bib13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000521511","article-title":"IgA nephropathy: a tale of 3 continents","volume":"2","author":"Tang","year":"2021","journal-title":"Glomerular Dis"},{"key":"2026101909245908000_bib14","doi-asserted-by":"publisher","first-page":"2251830","DOI":"10.1080\/21645515.2023.2251830","article-title":"Predictive overfitting in immunological applications: pitfalls and solutions","volume":"19","author":"Gygi","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"2026101909245908000_bib15","doi-asserted-by":"publisher","first-page":"836100","DOI":"10.3389\/fnins.2022.836100","article-title":"Ridge penalization in high-dimensional testing with applications to imaging genetics","volume":"16","author":"Gauran","year":"2022","journal-title":"Front Neurosci"},{"key":"2026101909245908000_bib16","doi-asserted-by":"publisher","first-page":"e0353489","DOI":"10.1371\/journal.pone.0353489","article-title":"Stability and interpretability of penalized logistic regression models for breast cancer risk prediction","volume":"21","author":"Okyere","year":"2026","journal-title":"PLoS One"},{"key":"2026101909245908000_bib17","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1200\/JCO-24-01372","article-title":"Combining response and toxicity data to implement Project Optimus","volume":"42","author":"Maki","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026101909245908000_bib18","first-page":"e111227","article-title":"Recent advances in the management of IgA nephropathy: from supportive care to targeted therapies","volume":"18","author":"Alroshodi","year":"2026","journal-title":"Cureus"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag345\/71606352\/sfag345.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/10\/sfag345\/71606352\/sfag345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/10\/sfag345\/71606352\/sfag345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:25:01Z","timestamp":1792416301000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag345\/8865298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag345","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10,1]]},"article-number":"sfag345"}}